Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

Table 1 Patient characteristics

Variables		Total(n = 93)	Group A(n = 46)	Gropu B(B = 47)	P value
Age, y	Median (range)	67 (40–74)	67 (49–74)	66 (40–74)	0.489
Sex	Male	52	28	24	0.406
Sex	Female	41	18	23
Smoking	Present or former smoker	52	28	24	0.406
Smoking	Non-smoker	41	18	23
ECOG PS	0	79	38	41	0.574
ECOG PS	1	14	8	6
Histology	Sq	5	2	3	1.000
Histology	Non-Sq	88	44	44
Pathological stage	IA (T > 2 cm)	51	24	27	0.679
Pathological stage	IB	42	22	20
EGFR-mutation	Positive	44	21	23	0.836
EGFR-mutation	Negative	49	25	24

ECOG PS Eastern Cooperative Oncology Group perfprmance status, Sq Squamous cell carcinoma, Non-Sq Non-squamous cell carcinoma, EGFR Epidermal growth factor receptor

ISSN: 1471-2407